Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EBITDA (2022 - 2025)

Historic EBITDA for CervoMed (CRVO) over the last 10 years, with Q3 2025 value amounting to -$7.7 million.

  • CervoMed's EBITDA fell 6743.81% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.7 million, marking a year-over-year decrease of 11737.39%. This contributed to the annual value of -$16.2 million for FY2024, which is 64748.84% down from last year.
  • Latest data reveals that CervoMed reported EBITDA of -$7.7 million as of Q3 2025, which was down 6743.81% from -$6.3 million recorded in Q2 2025.
  • Over the past 5 years, CervoMed's EBITDA peaked at $2.2 million during Q3 2023, and registered a low of -$7.7 million during Q3 2025.
  • For the 4-year period, CervoMed's EBITDA averaged around -$3.5 million, with its median value being -$2.8 million (2022).
  • In the last 5 years, CervoMed's EBITDA surged by 17683.45% in 2023 and then plummeted by 31441.4% in 2024.
  • Over the past 4 years, CervoMed's EBITDA (Quarter) stood at -$4.0 million in 2022, then skyrocketed by 41.3% to -$2.4 million in 2023, then crashed by 186.7% to -$6.8 million in 2024, then dropped by 13.98% to -$7.7 million in 2025.
  • Its EBITDA stands at -$7.7 million for Q3 2025, versus -$6.3 million for Q2 2025 and -$4.9 million for Q1 2025.